Zemplar
(Paricalcitol)ApprovedSmall molecule
AbbVieParicalcitol is used to treat low levels of parathyroid hormone and high phosphorus levels in people with chronic kidney disease. It helps regulate calcium and phosphorus balance in the body, especially in patients on dialysis.[2] Zemplar is currently approved and in use across 19 indications[4].[1]
Zemplar is one of 314 small molecule programs targeting Hyperparathyroidism. It is currently in Approved.
19
Indications
79
Total Trials
3
Active Trials
313
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 19 indications
Competition
Competitive Landscape
206 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Zemplar
AbbVieApproved
Amidate
PfizerPreclinical
Savaysa
Daiichi SankyoPreclinical
Xifaxan
SSalix
Preclinical
Oraverse
LLife Extension Foundation Inc.
Preclinical
Tamiflu
CConrado Roberto Hoffmann Filho
Preclinical
Potassium Iodide
MMeda Pharmaceuticals
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Jardiance
Boehringer IngelheimPreclinical
Optimal Medical Therapy
HHelios Health Institute GmbH
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Kidney Disease13 trials
Show 10 more trials
Secondary Hyperparathyroidism12 trials
Show 9 more trials
Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery
Completed·—·Phase 3·NCT01138475·49 enrolled
Pancreatic Cancer9 trials
Show 6 more trials
A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
Completed·—·Phase 1·NCT02030860·15 enrolled
Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer
Terminated·—·Phase 1·NCT03520790·36 enrolled
A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
Terminated·—·Phase 1·NCT03519308·3 enrolled
Dialysis Patients3 trials
32 more indications
Pancreatic Ductal Adenocarcinoma2 trials
Effectiveness2 trials
Stage 5 Chronic Kidney Disease2 trials
Anemia2 trials
Paricalcitol Improves Anemia of Inflammation
Terminated·—·Phase 4·NCT02876211·19 enrolled
Vitamin D2 trials
Alport syndrome1 trial
X-linked hypophosphatemic rickets1 trial
Multiple Myeloma1 trial
Diabetic Nephropathy1 trial
Inflammation1 trial
Prostate Cancer1 trial
Renal Transplant1 trial
Bone Disease1 trial
Nephropathy1 trial
Paricalcitol for the Treatment of Immunoglobulin A Nephropathy
Withdrawn·—·Phase 3·NCT00599963
Myelodysplastic Syndrome1 trial
Paricalcitol in Treating Patients With Myelodysplastic Syndrome
Completed·—·Phase 2·NCT00064376
Radiation Therapy1 trial
Erythropoietin1 trial
Fasting Conditions1 trial
Bioequivalence Study of Paricalcitol Capsules, 4 mcg Under Fasting Conditions
Completed·—·Phase 1·NCT02322632·69 enrolled
End-Stage Renal Disease1 trial
Unspecified4 trials
Regulatory
FDA Approval Timeline[5]
Feb 1, 2000
ZEMPLAR
NDA NDA020819
May 26, 2005
ZEMPLAR
NDA NDA021606
Oct 21, 2014
PARICALCITOL
NDA NDA201657
Nov 18, 2014
PARICALCITOL
NDA NDA205917
Feb 4, 2016
PARICALCITOL
NDA NDA207174
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Zemplar drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Paricalcitol. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]